NCT06673329 - Brodalumab in the Treatment of Immune-Related Adverse Events | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 11, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

November 30, 2026

Conditions

Breast CancerEsophageal CancerKidney CancerLung CancerThyroid CancerGynecologic CancerPancreatic CancerStomach CancerBrain TumorColon CancerRectal CancerHead and Neck CancerOral CancerLiver CancerSkin CancerProstate CancerTesticular CancerSolid Tumor

Interventions

DRUG

Brodalumab

Brodalumab 210 mg subcutaneous injection

RADIATION

CT scan

CT scans within 4 weeks of starting brodalumab and every 3 months during the study for tumor assessment

Trial Locations (1)

10032

RECRUITING

Columbia University Irving Medical Center, New York